{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:03:47Z","timestamp":1790244227385,"version":"4.1.0"},"reference-count":37,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>In recent years, there has been some impressive progress made in cancer research in terms of sophisticated new small-molecule drugs, particularly targeted drugs, and of immune, cell, and gene therapies, which have saved and prolonged the lives of many cancer patients [...]<\/jats:p>","DOI":"10.3390\/ijms27198511","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:07:54Z","timestamp":1790240874000},"page":"8511","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Special Issue \u201cRecent Advances of Novel Pharmaceutical Designs for Anti-Cancer Therapies, 3rd Edition\u201d"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7305-346X","authenticated-orcid":false,"given":"Bernhard","family":"Biersack","sequence":"first","affiliation":[{"name":"Organic Chemistry Laboratory, University of Bayreuth, Universit\u00e4tsstrasse 30, 95440 Bayreuth, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","article-title":"Exploring treatment options in cancer: Tumor treatment strategies","volume":"9","author":"Liu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_2","unstructured":"(2026, September 01). WHO Calls for Urgent Action as New Cancer Cases Are Projected to Nearly Double by 2050. Available online: https:\/\/www.who.int\/news\/item\/08-07-2026-who-calls-for-urgent-action-as-new-cancer-cases-are-projected-to-nearly-double-by-2050."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41392-026-02924-w","article-title":"Cancer drug response and resistance: Molecular mechanisms and combating strategies","volume":"11","author":"Cheng","year":"2026","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e076625","DOI":"10.1136\/bmj-2023-076625","article-title":"Illness trajectories of incurable solid cancers","volume":"384","author":"Geijteman","year":"2024","journal-title":"BMJ"},{"key":"ref_5","unstructured":"(2026, August 11). Recent Advances of Novel Pharmaceutical Designs for Anti-Cancer Therapies. Available online: https:\/\/www.mdpi.com\/journal\/ijms\/special_issues\/anticancer_pharmaceutical."},{"key":"ref_6","unstructured":"(2026, August 11). Recent Advances of Novel Pharmaceutical Designs for Anti-Cancer Therapies 2.0. Available online: https:\/\/www.mdpi.com\/journal\/ijms\/special_issues\/WP9M07N772."},{"key":"ref_7","unstructured":"(2026, August 12). Recent Advances of Novel Pharmaceutical Designs for Anti-Cancer Therapies, 4th Edition. Available online: https:\/\/www.mdpi.com\/journal\/ijms\/special_issues\/W21M2BVWU3."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.32604\/or.2025.067592","article-title":"Unraveling immunotherapy resistance in solid tumors: Decoding mechanisms and charting future therapeutic landscapes","volume":"33","author":"Wang","year":"2025","journal-title":"Oncol. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(24)00917-6","article-title":"Renal cell carcinoma","volume":"404","author":"Young","year":"2024","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Rysz, J., \u0141awi\u0144ski, J., Franczyk, B., and Gluba-Sagr, A. (2025). Immune checkpoint inhibitors in clear cell renal cell carcinoma (ccRCC). Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26125577"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Dong, R., Wang, J., Guan, R., Sun, J., Jin, P., and Shen, J. (2025). Role of oxidative stress in the occurrence, development, and treatment of breast cancer. Antioxidants, 14.","DOI":"10.3390\/antiox14010104"},{"key":"ref_12","first-page":"103","article-title":"The role of ERO1\u03b1 in modulating cancer progression and immune escape","volume":"2","author":"Johnson","year":"2020","journal-title":"J. Cancer Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13046-024-02990-4","article-title":"Biological mechanisms and clinical significance of endoplasmic reticulum oxidoreductase 1 alpha (ERO1\u03b1) in human cancer","volume":"43","author":"Chen","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Khojayeva, K., Moldasheva, A., and Aljofan, M. (2025). ERO1\u03b1 as a potential drug target for breast cancer: A systematic review of current evidence. Int. J. Mol. Sci., 26.","DOI":"10.22541\/au.175648036.63225061\/v1"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Graziano, G., Stefanachi, A., Contino, M., Prieto-D\u00edaz, R., Ligresti, A., Kumar, P., Scilimati, A., Sotelo, E., and Leonetti, F. (2023). Multicomponent reaction-assisted drug discovery: A time- and cost-effective green approach speeding up identification and optimization of anticancer drugs. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24076581"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/17460441.2018.1403420","article-title":"Recent developments concerning the application of the Mannich reaction for drug design","volume":"13","author":"Biersack","year":"2018","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"\u015awi\u0105tek, P., Glomb, T., Wiatrak, B., Nowotarska, P., G\u0119barowski, T., Wojtkowiak, K., Jezierska, A., and Strzelecka, M. (2025). New 1,2,4-triazole derivatives with a N-Mannich base structure based on a 4,6-dimethylpyridine scaffold as anticancer agents: Design, synthesis, biological evaluation, and molecular modeling. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26146572"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Pennel, K.A.F., Kurniawan, A., Samir Foad Al-Badran, S., Schubert Santana, L., Quinn, J., Nixon, C., Hatthakarnkul, P., Maka, N., Roxburgh, C., and McMillan, D. (2024). IL6 and IL6R as prognostic biomarkers in colorectal cancer. Biomolecules, 14.","DOI":"10.3390\/biom14121629"},{"key":"ref_19","first-page":"784","article-title":"The roles of the human ATP-binding cassette transporters P-glycoprotein and ABCG2 in multidrug resistance in cancer at endogenous sites: Future opportunities for structure-based drug design of inhibitors","volume":"4","author":"Goebel","year":"2021","journal-title":"Cancer Drug Resist."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Mustafa, S., Koran, S., and AlOmair, L. (2022). Insights into the role of matrix metalloproteinases in cancer and its various therapeutic aspects: A review. Front. Mol. Biosci., 9.","DOI":"10.3389\/fmolb.2022.896099"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Rashid, Z.A., and Bardaweel, S.K. (2023). Novel matrix metalloproteinase-9 (MMP-9) inhibitors in cancer treatment. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241512133"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Almutairi, S., Hajjo, R., Sabbah, D.A., Sweidan, K., Rashid, Z.A., and Bardaweel, S.K. (2025). Molecular and system-level characterization of MMP12 suppression in lung cancer: A combined bioinformatics and molecular approach. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms262411802"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Krauss, G. (2003). Biochemistry of Signal Transduction and Regulation, Wiley-VCH. [3rd ed.].","DOI":"10.1002\/3527601864"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Latosi\u0144ska, M., and Latosi\u0144ska, J.N. (2024). Serine\/threonine protein kinases as attractive targets for anti-cancer drugs\u2013an innovative approach to ligand tuning using combined quantum chemical calculations, molecular docking, molecular dynamic simulations, and network-like similarity graphs. Molecules, 29.","DOI":"10.3390\/molecules29133199"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Zeng, T., Liu, H., Li, Z., Liu, T., Zhang, K., and Wang, S. (2026). Exploring PIM1 kinase as a therapeutic target: Mechanisms and strategies in cancer treatment. Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27146303"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Wi\u0144ska, P., Wielechowska, M., Milewski, \u0141., Siedlecki, P., and \u0141ukowska-Chojnacka, E. (2025). Pro-apoptotic activity of 1-(4,5,6,7-tetrabromo-1H-benzimidazol-1-yl)propan-2-one, an intracellular inhibitor of PIM-1 kinase in acute lymphoblastic leukemia and breast cancer cells. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26125897"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.trecan.2026.03.004","article-title":"Targeting cyclin-dependent kinases in cancer: Emerging therapeutics and clinical strategies","volume":"12","author":"Tan","year":"2026","journal-title":"Trends Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41568-022-00456-3","article-title":"Targeting CDK4 and CDK6 in cancer","volume":"22","author":"Goel","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"He, L., Fu, Y., Tian, Y., Wang, X., Zhou, X., Ding, R.-B., Qi, X., and Bao, J. (2023). Antidepressants as autophagy modulators for cancer therapy. Molecules, 28.","DOI":"10.3390\/molecules28227594"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Li, Y., Sung, Y., Choi, Y.E., Choi, Y., and Goh, S.-H. (2024). Synergistic enhancement of antitumor effects by combining abemaciclib with desipramine. Int. J. Mol. Sci., 25.","DOI":"10.20944\/preprints202406.0371.v1"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Fernandez, A., Artola, M., Leon, S., Otegui, N., Jimeno, A., Serrano, D., and Calvo, A. (2025). Cancer vulnerabilities through targeting the ATR\/Chk1 and ATM\/Chk2 axes in the context of DNA damage. Cells, 14.","DOI":"10.20944\/preprints202503.2214.v1"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nrc2812","article-title":"PARP inhibition: PARP1 and beyond","volume":"10","author":"Rouleau","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"B\u0119benek, W., Gajek, A., Marczak, A., Mal\u00fd, J., Smejkal, J., Statkiewicz, M., Rusetska, N., Bry\u015b, M., and Rogalska, A. (2025). MK-8776 and olaparib combination acts synergistically in hepatocellular carcinoma cells, demonstrating lack of adverse effects on liver tissues in ovarian cancer PDX model. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26020834"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Ferro-Flores, G., Azor\u00edn-Vega, E., Ocampo-Garc\u00eda, B., Luna-Guti\u00e9rrez, M., Cruz-Nova, P., and Mel\u00e9ndez-Alafort, L. (2025). Effects of targeted radionuclide therapy on cancer cells beyond the ablative radiation dose. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26146968"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"pkag056","DOI":"10.1093\/jncics\/pkag056","article-title":"Emerging role of radiopharmaceutical therapy in oncology: Advances, challenges, and future directions","volume":"10","author":"Ordas","year":"2026","journal-title":"JNCI Cancer Spectr."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/cac2.70063","article-title":"Advances in radiopharmaceuticals for cancer radiotheranostics: CCK2R targeting as a paradigm for translational innovation","volume":"45","author":"Li","year":"2025","journal-title":"Cancer Commun."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Chang, M.-C., Chen, C.-T., Chiang, P.-F., Tang, I.-C., Peng, C.-L., Wang, Y.-F., Tai, Y.-J., and Chiang, Y.-C. (2025). Development of INER-PP-F11N as the peptide-radionuclide conjugate drug against CCK2 receptor-overexpressing tumors. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26146565"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/19\/8511\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:11:33Z","timestamp":1790241093000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/19\/8511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":37,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["ijms27198511"],"URL":"https:\/\/doi.org\/10.3390\/ijms27198511","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]}}}